Cardiovascular Medicine

2 pages, 156 KB

Open AccessCommunication

Jahresbericht 2003 der Schweizerischen Arbeitsgruppe WATCH (Working Group for Adults and Teenagers with Congenital Heart Disease) der SGK

by Thierry Carrel, Erwin Oechslin, Maurice Payot and Pedro Trigo-Trindade

Cardiovasc. Med. 2005, 8(5), 209; https://doi.org/10.4414/cvm.2005.01105 (registering DOI) - 27 May 2005

Viewed by 34

Abstract

WATCH hielt ihre administrative Sitzung anlässlich der Jahrestagung der SGK in Lausanne am Freitag, 9. Mai 2003 [...]. Full article

2 pages, 166 KB

Open AccessInteresting Images

Collatérales Veineuses Systémiques Après Dérivation Cavo-Pulmonaire Totale

by Pedro Trigo Trindade, Dominique Didier, Beat Friedli, Maurice Beghetti and Yacine Aggoun

Cardiovasc. Med. 2005, 8(5), 207; https://doi.org/10.4414/cvm.2005.01101 - 27 May 2005

Viewed by 33

Abstract

Une patiente de 18 ans, élève-infirmière, connue pour une cardiopathie congénitale [...] Full article

► Show Figures

Figure 1

3 pages, 204 KB

Open AccessInteresting Images

Apikale Hypertrophe Kardiomyopathie—Vom EKG zur Diagnose

by Susanne Buchholz and Thomas Herren

Cardiovasc. Med. 2005, 8(5), 204; https://doi.org/10.4414/cvm.2005.01099 - 27 May 2005

Viewed by 39

Abstract

Der 54jährige, aus Sri Lanka stammende Patient verspürte bei seiner Tätigkeit als Landwirt eine zunehmende Müdigkeit unter Belastung sowie ein «Schweregefühl» in der Brust [...] Full article

► Show Figures

Figure 1

14 pages, 253 KB

Open AccessEditorial

Nebivolol: Selektiver β₁-Rezeptorenblocker mit NO-Modulierender Vasodilatation

by Christiane Brockes and Paul Erne

Cardiovasc. Med. 2005, 8(5), 190; https://doi.org/10.4414/cvm.2005.01104 - 27 May 2005

Viewed by 41

Abstract

Nebivolol is a selective cardiac receptor antagonist, which mediates the release of endothelial nitric oxide (NO) and provides protection for the arteries and organs. Nebivolol improves the endothelial dysfunction and reduces the heart rate: owing to the combined dual mechanism of action, a [...] Read more.

Nebivolol is a selective cardiac receptor antagonist, which mediates the release of endothelial nitric oxide (NO) and provides protection for the arteries and organs. Nebivolol improves the endothelial dysfunction and reduces the heart rate: owing to the combined dual mechanism of action, a high number of hypertensives reach the desirable blood pressure values. Additionally, the overall heart function is positively influenced by nebivolol: actual results from the SENIORS study demonstrate, that nebivolol powerfully increases the prognosis in elderly heart failure patients. The high-selective beta-blocker significantly reduces the composite primary endpoint of all-cause mortality or cardiovascular hospital admission. Nebivolol has an excellent tolerability and a high safety profile: therefore nebivolol may be recommended as a useful first-line treatment option for the management of patients with essential hypertension.
Full article

3 pages, 196 KB

Open AccessCase Report

Impella Assisted High Risk Percutaneous Coronary Intervention

by Stephan Windecker and Bernhard Meier

Cardiovasc. Med. 2005, 8(5), 187; https://doi.org/10.4414/cvm.2005.01098 - 27 May 2005

Cited by 1 | Viewed by 40

Abstract

Percutaneous left ventricular assist devices provide temporary circulatory support as bridge to recovery or heart transplantation in case of severe left ventricular failure and during percutaneous high-risk revascularisation procedures. We describe the first Swiss case of a high risk percutaneous coronary intervention assisted [...] Read more.

Percutaneous left ventricular assist devices provide temporary circulatory support as bridge to recovery or heart transplantation in case of severe left ventricular failure and during percutaneous high-risk revascularisation procedures. We describe the first Swiss case of a high risk percutaneous coronary intervention assisted by a new, percutaneously inserted left ventricular assist device: the Impella Recover^® LP 2.5 pump. Full article

► Show Figures

Figure 1

6 pages, 204 KB

Open AccessArticle

Predictive Value of Clinical Risk Assessment Tools and Guidelines for 10-Year Coronary Heart Disease Risk in Practice-Based Primary Care

by Michel J. Romanens, David C. Berger and Edouard J. Battegay

Cardiovasc. Med. 2005, 8(5), 180; https://doi.org/10.4414/cvm.2005.01103 - 27 May 2005

Cited by 1 | Viewed by 37

Abstract

Background: Risk for developing myocardial infarction derived from risk tables in primary care subjects in Switzerland may over- or underestimate risk. Coronary calcifications may improve the performance of risk tables. Methods: We used coronary calcium score percentiles >50 (CS% >50) as [...] Read more.

Background: Risk for developing myocardial infarction derived from risk tables in primary care subjects in Switzerland may over- or underestimate risk. Coronary calcifications may improve the performance of risk tables. Methods: We used coronary calcium score percentiles >50 (CS% >50) as a surrogate marker for 10-year myocardial infarction risk in a prospective cross-sectional monocenter study. CS% >50 was compared to several risk charts, was used to reclassify subjects in the intermediate risk category assessed by Framingham risk scores (FRS), and was used to calculate a cohort specific correction factor for FRS and PROCAM. Results from risk charts were entered into the Bayes formula as the pretest risk estimates. Subjects in our cohort were 100 primary care patients with no known history of cardiovascular disease randomly selected from three primary care practices. Results: The sensitivity of FRS to detect CS% >50 was 47%, and specificity was 85%. NCEP III and Swiss guidelines had sensitivities of 53% and 67%, respectively (p = ns), and specificities of 66% and 67% (p <0.05). In 21 subjects with intermediate risk as assessed by FRS, CS% >50-derived post-test probabilities shifted 16 subjects (76%) into the low-risk category and 5 subjects (24%) into the high-risk category. Cohort-specific correction factors were 0.68 for FRS and 0.64 for PROCAM. Conclusions: For our Swiss German cohort, FRS and PROCAM tended to overestimate risk. A biological risk marker (coronary calcifications) may allow improvement of risk prediction in primary care subjects with intermediate risk and also helps in the calculation of cohort-specific correction factors. Full article

► Show Figures

Figure 1

6 pages, 235 KB

Open AccessProceeding Paper

Coronary Revascularisation in Diabetics: Surgical Aspects

by Thierry Carrel and Lars Englberger

Cardiovasc. Med. 2005, 8(5), 172; https://doi.org/10.4414/cvm.2005.01100 - 27 May 2005

Viewed by 35

Abstract

Recent advances in percutaneous coronary intervention (PCI) techniques and progress made with drug-eluted stents as well as with post-interventional anti-thrombotic management have increased the number of patients with three vessel coronary artery disease who are nowadays initially treated interventionally. However, coronary artery bypass [...] Read more.

Recent advances in percutaneous coronary intervention (PCI) techniques and progress made with drug-eluted stents as well as with post-interventional anti-thrombotic management have increased the number of patients with three vessel coronary artery disease who are nowadays initially treated interventionally. However, coronary artery bypass grafting (CABG) has proven to be as effective as percutaneous methods, although these approaches are selected for different states of the disease. This is especially true for diabetic patients who generally demonstrate a greater mid- to long-term benefit following CABG than PCI. Nevertheless, surgery should also integrate the most recent advances like total arterial revascularisation and off-pump techniques in selected cases. Full article

► Show Figures

Figure 1

4 pages, 212 KB

Open AccessEditorial

Von den Kardiovaskulären Risikofaktoren zum Global Risk Assessment: Confused at a Higher Level Oder Wirklicher Fortschritt?

by Thomas F. Lüscher and Jens P. Hellermann

Cardiovasc. Med. 2005, 8(5), 167; https://doi.org/10.4414/cvm.2005.01102 - 27 May 2005

Viewed by 36

Abstract

Kardiovaskuläre Risikofaktoren wie die arterielle Hypertonie, das Cholesterin, die Zucker-krankheit u.a.m. hatten sich in den 1960er und 1970er Jahren langsam zur Bestimmung der Prognose durchgesetzt [...] Full article

Journal Menu

Journal Browser

Cardiovasc. Med., Volume 8, Issue 5 (05 2005) – 8 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI